LC600: evidence on adverse reactions
A levocarnitine medicine label describes severe allergic reactions after intravenous administration, mostly in dialysis patients. Postmarketing reports also include seizures with oral or intravenous use. These reports cannot establish event frequencies. [1]
These findings concern medicinal levocarnitine preparations. They do not establish safety of a particular LC600 laboratory-powder batch or equivalence to a medicine. [1]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Severe allergic reactions | Patients, mostly on dialysis; medicinal levocarnitine intravenously (official medicine label) | Described in the label; these reports cannot establish event frequencies | [1] |
| Seizures | Postmarketing reports, levocarnitine orally or intravenously | Reported after marketing; frequency cannot be established | [1] |
References
- Baxter Healthcare Corporation (2026). Levocarnitine injection, solution: official Baxter label.